Literature DB >> 1141808

Inhibition of oestrogen-stimulated prolactin release by anti-oestrogens.

V C Jordan, S Koerner, C Robison.   

Abstract

Mesh：

Substances：

Year:  1975        PMID： 1141808     DOI： 10.1677/joe.0.0650151

Source DB:  PubMed          Journal:  J Endocrinol        ISSN： 0022-0795            Impact factor:   4.286


× No keyword cloud information.
  6 in total

Review 1.  Regulation of insulin-like growth factors by antiestrogen.

Authors:  R Winston; P C Kao; D T Kiang
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

2.  Comparison between tamoxifen and clomiphene therapy in women with anovulation.

Authors:  I Gerhard; B Runnebaum
Journal:  Arch Gynecol       Date:  1979

Review 3.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 4.  Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 5.  Tamoxifen reduces serum insulin-like growth factor I (IGF-I).

Authors:  M N Pollak; H T Huynh; S P Lefebvre
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

6.  The effect of tamoxifen on GH and PRL secretion by human pituitary tumors.

Authors:  S W Lamberts; M de Quijada; J G Klijn
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.